

### **Omrix Biopharmaceuticals to raise up to \$80.5m in NY**

*The company has filed a prospectus with the SEC. Company value for the issue will reportedly be \$300-350 million.*

Tali Tsipori 19 Jan 06 18:14

Omrix Biopharmaceuticals Ltd. filed a draft prospectus with the US Securities and Exchange (SEC) yesterday. Omrix, a maker of biological sealants for surgery and passive inoculations, wants to raise up to \$80.5 million. The company did not disclose in the prospectus the value at which it wants to go public, but it is reportedly be \$300-350 million.

The lead underwriters for the IPO are UBS (which will be the sole book runner) and CIBC. The secondary underwriters will be Oppenheimer & Co. Inc. and Leerink Swann. If the issue goes ahead as planned, Omrix will be traded under the symbol OMRI.

Founded in Belgium in 1995, Omrix has a production facility in Kiryat Ono and a development center in Rehovot. The company's headquarters are on Third Avenue in New York. In its prospectus, the company says the proceeds from the issue will used to expand its production capacity, penetrate on of the human surgical sealant markets in Japan and other countries, and finance working capital for other general purposes. The prospectus says the company has raised a gross \$58.1 million since it was founded.

Omrix was founded by president and CEO Robert Taub, who previously founded Swiss-Austrian biopharmaceutical company Octapharma AG, which he ran for 12 years. Taub is the largest shareholder in Omrix, with 32.1% of its shares. Other major shareholders are MPM Capital, a venture capital fund that invests in biotechnology companies (29.5%); AlInvest Partners (8%); and Capricorn Venture Partners (8.9%).

Published by Globes [online], Israel business news - [www.globes.co.il](http://www.globes.co.il) - on January 19, 2006